

Thurrock Medicines Management & Safety Group

16th March 2016

The Thames Room, Civic Offices

Present:	Francoise Price (FP)	Interim Head of Medicines Optimisation Team
	Jonathan Andrews (JA)	Deputy Head and Implementation Lead
	Marie McIlwain (MM)	Senior Clinical and Implementation Pharmacist
	Linda Smart (LS)	Deputy Chief Nurse
	Dr Deshpande (Dr D)	Chair of NHS Thurrock CCG Board and local GP
	Dr Nimal Raj (Dr NR)	GP Board Member
	Leigh Ann Paterson (LP)	Business Support Team (minutes)
Apologies	Joanne Mayhew	Southend CCG
	Laura Davies	Lead Nurse
	Dr Martin	GP Board Member

1.	Welcome/Apologies and declarations of interest
	Apologies given. Dr D and Dr NR made a declaration in reference to the Prescribing Incentive Scheme 16/17.
2.	Minutes of the meeting held on 19.02.16
	Agreed as a correct record.
3.	Action Log
	<p>Action 1 – ToR discussed suggested changes made. FP agreed to update and issue to group before next group for final ratification. LAP to check with N Meeks whether this is a group or committee with the TCCG constitution so wording in ToR can be changed appropriately. ACTION: LAP to check whether group or committee. FP to update ToR with changes and share with group.</p> <p>Action 2 – Confirmed hyperhidrosis document is loaded onto webpage. Action can be closed.</p> <p>Action 3 – FP confirmed this is being finalised with N Meeks. Going to next Information Governance group for final approval.</p> <p>Action 4 – LAP confirmed action completed and can be closed.</p>
4.	Matters arising not on agenda
	No other matters raised.
5.	Updated ToR
	As per action log ToR to be updated and distributed.

<p>6.</p>	<p>Finance Report and QIPP 15/16</p> <p>JA ran through the finance report. £21.2M spend. £22.2M forecast outturn. £1M overspend showing in December data.</p> <p>Aveley MC is a major overspending practice. Medicines Optimisation have assigned a sessional pharmacist from the team to help support work to improve this.</p> <p>QIPP projects on target to over deliver.</p> <p>Rebates have been in place since October. Only drugs on formulary and/or agreed by PresQIPP Rebate Committee are signed up to rebates. Rebates for consideration will be brought to this group. The rebates are disclosed on the monthly finance report and an annual report will be submitted to the Audit committee</p>
<p>7.</p>	<p>QIPP 16/17</p> <p>FP ran through the QIPP projects for 16/17:</p> <ul style="list-style-type: none"> - Medicines Optimisation - Rebates - Wastage - CMPA Nutritional - Stoma (which may become a transformational project) <p>FP confirmed there is a stoma guidance document available, which would be shared with the group.</p> <p>ACTION: MOT to share stoma guidance.</p>
<p>8.</p>	<p>NICE TAs NICE MHRAs</p> <p>FP ran through the NICE guidance. Highlighting the important information like clinical guidelines and NICE advice.</p> <p>Medicines Optimisation Patient Safety and Quality report also highlighted MHRA alerts and incidents locally to show lessons learnt.</p> <p>Dr D asked how we monitor these incidents. It was confirmed this document was for information but was primarily for the Quality and Safety Group. JA suggested this could be brought into the Prescribing Incentive Scheme as a bi-monthly action.</p> <p>It was suggested that the warfarin alert and information about highly addictive drugs could be added to the next prescribing newsletter.</p> <p>There also could be a patient safety focused newsletter in the future, with maybe case studies etc.</p> <p>ACTION: MM to add to future prescribing newsletters.</p> <p>FP stated that the CCG does not legally need a Control Drug Accountable Officer as CCGs are not defined as designated bodies. CCGs are however required to assist the relevant NHSE's lead CDAO, for example, in investigating concerns or analysing data. It is good practice for the CCG to nominate a relevant individual within the CCG who will act as focal point for liaison with the NHSE lead CDAO.</p> <p>FP also mentioned that there was an imbedded document within the Medicines Optimisation Patient Safety and Quality report that was around opioid aware. Agreed to share with group with minutes.</p> <p>ACTION: MOT to share opioid document with group.</p>

9.	Rebates for Consideration
	None.
10.	Outline PIS 16/17
	<p>JA confirmed the Prescribing Incentive Scheme for 16/17 will be launched in April.</p> <p>The MOT are currently finalising the targets. The group were asked to share and give ideas and thoughts back to MOT within the next 10 working days so the scheme could be finalised.</p> <p>ACTION: Group to comment on PIS targets.</p>
11.	Practice Visits 16/17
	JA confirmed this year's practice visits will start in April, concentrating on outliers within the patch.
12.	AOB
	Dr NR asked about pain management pathways for neuropathic pain. It was confirmed this was on the MOT webpage.
Date of Next Meeting	
Wednesday 15 th April 2:30pm.	